KUALA LUMPUR, Oct 23 (Bernama) -- Recursion, a clinical stage TechBio company, announced the first patient has been dosed in its Phase 2 clinical trial of REC-3964, a potential first-in-class, oral ...
Artificial intelligence (AI)-based drug developer Recursion has dosed the first patient in its Phase II ALDER trial (NCT06536465) assessing its first new chemical entity to be developed through its ...
Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs Platform will ...
Hi guys. I'm new here. I've joined these forums due to a recommendation from a friend of mine. He says that you guys here can offer some good programming repair work if guys like me are in trouble.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback